Recap: Corbus Pharmaceuticals Q2 Earnings

 

Shares of Corbus Pharmaceuticals CRBP decreased 1.5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 71.15% year over year to ($0.15), which missed the estimate of ($0.12).

Revenue of $136,558 decreased by 52.31% year over year, which missed the estimate of $870,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Corbus Pharmaceuticals hasn't issued any revenue guidance for the time being.

Price Action

Company's 52-week high was at $9.78

52-week low: $0.91

Price action over last quarter: down 21.56%

Company Description

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!